In addition to sponsoring its own research and collaborations, Lilly has programs for considering external requests for Lilly provision of study drug and/or financial support for external studies that are initiated, designed and sponsored by external researchers.
Lilly's Competitive Clinical Research Grant consist of publicly posted Request for Proposal (RFP) which includes details of specific areas of interest and timelines for review and approval. Researchers are encouraged to review the RFP, download the proposal form, and submit the completed proposal by the date specified in each RFP. Approved research proposals will be the responsibility of the grantee for the design, conduct and regulatory sponsorship. Initial reviews of the proposals are carried out by global committees comprised of Lilly medical and scientific staff members from relevant therapeutic areas. An external committee may be utilized to review and select the final proposals for approval.
Grant Opportunities
When you complete the proposal form, please email it to the designated email address in “Submit a Proposal”.
| Title | Application Due Date | Country | Focus Area | RFP Issue Date | Actions |
| Use of lebrikizumab in patients with Atopic Dermatitis (AD) and allergic comorbid conditions, such as asthma, food allergies, and others View RFP (PDF) | 2025-04-15T00:00:00.000Z | United States | Dermatology | 2025-02-01T00:00:00.000Z | |
| Assess lebrikizumab effectiveness in patients with Atopic Dermatitis (AD) identified with use of the “Guide to Advance Systemic Therapy in AD”. View RFP (PDF) | 2025-04-15T00:00:00.000Z | United States | Dermatology | 2025-02-01T00:00:00.000Z | |
| Explore the effectiveness of lebrikizumab therapy in patients with moderate-to-severe atopic dermatitis (AD) and flares View RFP (PDF) | 2025-04-15T00:00:00.000Z | United States | Dermatology | 2025-02-01T00:00:00.000Z | |
| The efficacy of Mirikizumab treatment in the over 60 population with moderate to severe Crohn’s disease and/or moderate to severe ulcerative colitis View RFP (PDF) | 2024-11-15T00:00:00.000Z | United States | Gastroenterology | 2024-09-15T00:00:00.000Z | |
| The efficacy of Mirikizumab treatment in patients with perianal Crohn’s disease View RFP (PDF) | 2024-11-15T00:00:00.000Z | United States | Gastroenterology | 2024-09-15T00:00:00.000Z | |
| Transmural healing with Mirikizumab treatment in patients with moderate to severe ulcerative colitis and/or moderate to severe Crohn’s disease View RFP (PDF) | 2024-11-15T00:00:00.000Z | United States | Gastroenterology | 2024-09-15T00:00:00.000Z |